Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Novartis Actigall

Executive Summary

Novartis Actigall: Company launches ursodiol capsules for the prevention of gallstones in obese patients experiencing rapid weight loss. The supplemental indication was cleared by FDA in March 1996. The cost of the recommended course of therapy (300 mg taken twice daily for 4-6 months) is between $545 and $815 AWP. Novartis will support the launch with direct mail to physicians, but is not using its detail force...
UsernamePublicRestriction

Register

PS030186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel